Financial Planning Hawaii Inc. Invests $2.90 Million in AbbVie Inc. $ABBV

Financial Planning Hawaii Inc. bought a new stake in AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,673 shares of the company’s stock, valued at approximately $2,896,000. AbbVie makes up approximately 1.7% of Financial Planning Hawaii Inc.’s portfolio, making the stock its 13th largest position.

A number of other hedge funds have also bought and sold shares of the business. Chelsea Counsel Co. bought a new stake in shares of AbbVie during the 3rd quarter worth $26,000. Westend Capital Management LLC bought a new position in AbbVie during the fourth quarter valued at about $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the third quarter valued at about $31,000. Evolution Wealth Management Inc. purchased a new stake in AbbVie during the second quarter worth about $26,000. Finally, Caitlin John LLC bought a new stake in AbbVie in the third quarter worth about $33,000. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Guggenheim reiterated a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Piper Sandler increased their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Finally, UBS Group decreased their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Up 1.8%

ABBV stock opened at $213.12 on Tuesday. The stock has a 50-day simple moving average of $221.93 and a two-hundred day simple moving average of $224.66. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The firm has a market capitalization of $376.83 billion, a PE ratio of 90.30, a PEG ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the firm posted $2.16 earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.